ObjectiveTo explore the effect of domestic Atorvastatin on patients with Pulmonary Arterial Hypertension（PAH） and its mechanism. MethodsFrom January 2008 to January 2012, a total of 52 inpatients with PAH in our hospital were enrolled, including 28 patients with PAH induced by pulmonary shunt (CAD-PAH), 16 patients with idiopathic PAH (IPAH), and 16 patients with PAH related with connective tissue diseases(CTD-PAH). All patients were randomly and equally divided into control group (conventional therapy) and observation group (conventional therapy and domestic Atorvastatin, 20 mg/d). Mean pulmonary arterial pressure (mPAP), arterial blood gas analysis (PaO2), echocardiography changes in right ventricular diameter (RVD), 6 Minutes Walking distance (6MWD), creatine kinase (CK) and transaminases (ALT/AST) were measured before treatment and 6 months after the treatment. Results(1) After 6 months treatment, mPAP in the observation group was lower than that in the control group and that before the treatment (P＜0.05). (2) After treatment, PaO 2 in both group was higher than that before treatment, and the improvement was more obvious in the control group(P＜0.01，P＜0.05). (3) There was no significant difference in RVD before and after treatment (P＞0.05). (4) 6MWD in the two groups was increased after treatment, but there was no significant difference between two groups(P＞0.05). (5) No adverse reactions such as muscle pain and increase of CK and ALT/AST were reported (P＞0.05). ConclusionsDomestic Atorvastatin can decrease mPAP and increase PaO2 in PAH patients after six-month treatment. Yet the improvement of RVD and exercise capacity were not obvious, which might be related to the small sample size and the short-term observation on treatment. Further investigation is expected to explore the long-term effect of domestic Atorvastatin.

• ref